HLA-B27.5/B2M
Nomenclature
C57BL/6JSmo-B2mem1(hB2M-linker-HLA-B*2705/H2-D1)Smoc
Cat. NO.
NM-HU-261003
Strain State
Repository Live
Gene Summary
Gene Symbol
B2M
Model Description
Validation Data
Fig.1 Detection of hB2M and mH2D expression on leukocytes in blood of WT C57BL/6 mice and HLA-B27.5/B2M mice by FACS. Leukocytes were collected from wild-type C57BL/6 mice (8 weeks old) and HLA-B27.5/B2M humanized mice (13 weeks old), and analyzed by flow cytometry with anti-mB2M, anti-hB2M, anti-HLA-ABC and anti-mH2D.
Abbr. WT, wild type.
Fig.2 Detection of hB2M and mH2D expression on leukocytes in spleen of WT C57BL/6 mice and HLA-B27.5/B2M mice by FACS. Leukocytes were collected from wild-type C57BL/6 mice (8 weeks old) and HLA-B27.5/B2M humanized mice (13 weeks old), and analyzed by flow cytometry with anti-mB2M, anti-hB2M, anti-HLA-ABC and anti-mH2D.
Abbr. WT, wild type.
You may also like
Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreWorkshop：Progress and Advances in Preclinical immuno-Oncology Research
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Learn moreCustomizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more
